ZS Pharma presents new data from ZS003 two week phase 3 trial
ZS Pharma announced results of a secondary analysis of ZS003, a two week pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate), its investigational treatment for hyperkalemia. The analysis showed that once-daily dosing of ZS-9 prevented the recurrence of hyperkalemia. September 15, 2014